Crinetics Pharmaceuticals Analyst Sees Around 70% Upside For Stock, Cites More Investor Interest In Endocrinology
Stifel initiates coverage on CRNX, a clinical-stage pharmaceutical company focused on endocrine diseases and tumors.
Fintel on MSN17h
Stifel Initiates Coverage of Crinetics Pharmaceuticals (CRNX) with Buy Recommendation
Fintel reports that on March 25, 2025, Stifel initiated coverage of Crinetics Pharmaceuticals (NasdaqGS:CRNX) with a Buy recommendation. Analyst Price Forecast Suggests 114.68% Upside As of March 19, ...